1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Market Spotlight: Celiac Disease, Pharma Intelligence

Market Spotlight: Celiac Disease, Pharma Intelligence

  • August 2019
  • 27 pages
  • ID: 5780154
  • Format: PDF
  • By Pharma Intelligence


Table of Contents

This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

Key Takeaways
The analyst estimates that in 2017, there were approximately 89.9 million prevalent cases of celiac disease worldwide, and forecasts that number to increase to 98.8 million prevalent cases by 2026.
Prevalence of celiac disease is highest in Europe and Northern America, and lowest in Africa and Oceania.
All industry-sponsored drugs in active clinical development for celiac disease are in Phase I or Phase II. Therapies in development for celiac disease focus on targets such as gluten, interleukin-15, interleukin-15 receptor, zonulin and zonulin receptor, immune system, and T-cell receptor. Pipeline drugs for celiac disease are administered orally, as well as via the subcutaneous, intradermal, and intravenous routes.
The release of topline Phase III trial results for INN-202 is the only high-impact upcoming event in the celiac disease space. The overall likelihood of approval of a Phase I autoimmune/immunology asset is 14.7%, and the average probability a drug advances from Phase III is 68.9%. Drugs, on average, take 8.8 years from Phase I to approval in the overall autoimmune/immunology space.
There have been five licensing and asset acquisition deals involving celiac disease drugs during 2014–19. The largest deal during the period was the $170m licensing and co-development agreement signed in 2018 between Amgen and Provention Bio for the development of anti-IL-15 antibody AMG 714 for the treatment of gluten-free diet non-responsive celiac disease.
The distribution of clinical trials across Phase I–III indicates that the vast majority of trials for celiac disease have been in the mid and late phases of development, with 91% of trials in Phase II–III, and only 9% in Phase I.
The US has a substantial lead in the number of celiac disease clinical trials globally. Innovate Biopharmaceuticals has the highest number of completed trials for celiac disease, with six trials, and also leads industry sponsors with the highest number of clinical trials for celiac disease overall.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Toll Like Receptor 4 - Pipeline Review, H2 2019

Toll Like Receptor 4 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Toll Like Receptor 4 - Pipeline Review, H2 2019SummaryToll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, ...

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2019

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2019

  • $ 2000
  • August 2019

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, ...

Diarrhea - Pipeline Review, H2 2019

Diarrhea - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Diarrhea - Pipeline Review, H2 2019SummaryPharmaceutical and Healthcare disease pipeline guide Diarrhea - Pipeline Review, H2 2019, provides an overview of the Diarrhea (Gastrointestinal) pipeline lan ...

Colitis - Pipeline Review, H2 2019 $ 2000 September 2019


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on